Lancet
-
Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention. ⋯ UK Medical Research Council, British Heart Foundation, Cancer Research UK, and the European Community Biomed Programme.
-
Whether intensive control of glucose reduces macrovascular events and all-cause mortality in individuals with type 2 diabetes mellitus is unclear. We undertook a meta-analysis of randomised controlled trials to determine whether intensive treatment is beneficial. ⋯ None.